ICML 2025 | Insights into the HoLISTIC Consortium & the value of this initiative

We’re really excited about the HoLISTIC Consortium. This is an NIH-funded global consortium that started about seven, eight years ago. Multi-PI with myself and Dr Susan Parsons at Tufts University. Started small, but believe it or not, but already now, after several years of a lot of collaboration and stakeholder engagement has over 30,000 patients of individual patient files from basically all, almost all, I won’t say all, almost all seminal clinical trials in Hodgkin lymphoma for early stage and advanced stage for adults conducted in the last 15 to 20 years. And this is V studies, RAPID, RATHL, EORTC-H10, NCIC, now the German Hodgkin Study Group are excellent collaborators. And so about 20, 22,000 of that 30,000 are from seminal clinical trials, but importantly about 7 to 8,000 are from active cancer registries. So more real-world, kind of all-comers, not just clinical trial participants, number one, for the registries, but number two, those are enriched with long-term follow-up. So the median follow-up is 15 plus years where you can study those post-acute late effects. And we’re really doing it to come up with yes prediction models as we talked about, but we want to start layering in of course what happens after your PET scan is positive or negative down the road, interim or end of treatment. What about different treatment options? Then recalibrate the scores and importantly a next step early next year we’ll start to do with our methodologists and epidemiologists will be really estimating post-acute late effects, at least cardiovascular, and second cancers based on the treatments received on thousands and thousands of other patients. And then you do simulations millions of times. So it’s really just more data, objective data, to help inform patients and providers and family members. In the future, could we incorporate biology like ctDNA to the models? Of course, quality of life, cost of care, which I think will be really important, especially now that we have cure rates over 90%. We’re going to need these in silico big data models to help inform not just treatment decisions, but future clinical trial design. So it’s just been a lovely worldwide collaboration with just incredible engagement. And we’re really excited about the future of that consortium.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.